News

The company intends to provide data from trial evaluating cardiovascular outcomes with sitagliptin (TECOS), which includes prescribing information of sitagliptin-containing medicines. The TECOS trial, which involved 4,724 patients

Under the terms of the license agreement, Immune-Onc will acquire the exclusive global rights to develop and commercialize novel biotherapeutics with applications in cancer immunotherapy and other diseases. 

The data demonstrated that serum phosphorus levels, rickets, growth rates, and other functional outcomes improved with burosumab, and these treatment effects were sustained through 64 weeks of treatment.

HoFH is an inherited disorder, which can result in premature cardiovascular disease due to high levels of LDL cholesterol. Evinacumab is an investigational monoclonal antibody to angiopoietin-like protein

Safinamide is currently under clinical development by Meiji in Japan. Under the agreement, Eisai will obtain exclusive rights to safinamide to market in Japan and to develop and

FIN-524 is a live biotherapeutic product in pre-clinical research. It is composed of cultured bacterial strains that have been linked to favorable clinical outcomes in studies of microbiota

The trial had assessed the efficacy, safety and tolerability of a single administration of two different doses of Botox, including 30 units (30U) or 50 units (50 U),

The Phase 2a single-dose trial is being conducted in the United Kingdom. The primary objective of this double-blind, placebo-controlled study will evaluate the pharmacokinetic and pharmacodynamics profile and

The Company has retained Stifel, Nicolaus & Company, Incorporated to serve as its financial advisor in the process. Aviragen Therapeutics does not have a defined timeline for the